Head to Head Contrast: VolitionRx (NYSE:VNRX) vs. IDEXX Laboratories (NASDAQ:IDXX)

VolitionRx (NYSE:VNRX) and IDEXX Laboratories (NASDAQ:IDXX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings and Valuation

This table compares VolitionRx and IDEXX Laboratories”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VolitionRx	$770,000.00	69.17	-$35.32 million	($0.36)	-1.60
IDEXX Laboratories	$3.90 billion	9.66	$845.04 million	$10.67	43.09

IDEXX Laboratories has higher revenue and earnings than VolitionRx. VolitionRx is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares VolitionRx and IDEXX Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VolitionRx	-2,321.14%	N/A	-163.39%
IDEXX Laboratories	22.78%	55.82%	26.48%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for VolitionRx and IDEXX Laboratories, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VolitionRx	0	1	2	0	2.67
IDEXX Laboratories	0	3	6	1	2.80

VolitionRx currently has a consensus target price of $3.75, suggesting a potential upside of 552.51%. IDEXX Laboratories has a consensus target price of $533.75, suggesting a potential upside of 16.09%. Given VolitionRx’s higher probable upside, research analysts plainly believe VolitionRx is more favorable than IDEXX Laboratories.

Risk and Volatility

VolitionRx has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.

Insider & Institutional Ownership

8.1% of VolitionRx shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 12.8% of VolitionRx shares are held by company insiders. Comparatively, 2.1% of IDEXX Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

IDEXX Laboratories beats VolitionRx on 12 of the 15 factors compared between the two stocks.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

About IDEXX Laboratories

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.